What this Trial Is About

Researchers are studying how vancomycin behaves in the body of patients with acute kidney injury (AKI) who are receiving continuous renal replacement therapy (CRRT) using continuous veno-venous hemodiafiltration (CVVHDF) with the oXiris membrane. The oXiris membrane is designed to absorb inflammatory substances, and previous studies suggest it may reduce vancomycin levels by about 20%. Since there is limited data on this effect in living patients, this study aims to measure vancomycin levels to understand its pharmacokinetics when using this membrane. Participants receive vancomycin doses ranging from 7.5 to 10 mg/kg while undergoing CRRT with the oXiris membrane. Blood samples are collected from an arterial line before the dose and at multiple time points afterward (2, 3, 4, 5, 6, 8, and 12 hours) to assess how the drug is processed over time. The area under the curve (AUC) for vancomycin concentration is calculated to evaluate drug exposure and behavior in these patients. During the study, patients are monitored in the intensive care unit and have blood drawn at specified times to track vancomycin levels. Researchers analyze these samples to report the drug’s pharmacokinetic profile in patients with AKI receiving CRRT with the oXiris membrane. The study focuses on safety and detailed drug monitoring to better understand vancomycin dosing in this setting.

Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane